Evaluation of progesterone receptors with different cutoff values according to menopausal status in hormone-positive early breast cancer
Authors:
Open Access
- 14 November 2025
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 40023
Abstract
The impact of progesterone receptor (PR) expression level on breast cancer prognosis in relation to menopausal status is unclear. This study evaluated the impact of the association between PR expression level and menopausal status on prognosis in patients with estrogen receptor (ER)-positive (> 10%)/human epidermal growth factor receptor 2 (HER2)-negative breast cancer. We retrospectively identified 2,796 patients with ER-positive/HER2-negative early breast cancer and classified them into three groups based on PR expression levels: PR-high (> 10%), PR-low (1–10%), and PR-zero (< 1%). We compared the cumulative incidence of any recurrence (AR) and distant recurrence (DR) among the three groups by menopausal status. Over a median follow-up of 84.5 months, there were 324 AR and 264 DR events. In premenopausal patients, the PR-zero group (1,155 patients) had a significantly worse prognosis than did the PR-low (44 patients) and PR-high (60 patients) groups. Meanwhile, postmenopausal patients in the PR-zero (219 patients) and PR-low (167 patients) groups had similar prognosis, both significantly worse than the PR-high group (1,151 patients). Varying cutoff values of PR expression according to menopausal status could help determine more personalized treatment strategies.Keywords
This publication has 33 references indexed in Scilit:
- The clinical value of progesterone receptor expression in luminal breast cancer: A study of a large cohort with long‐term follow‐upCancer, 2023
- Current and future burden of breast cancer: Global statistics for 2020 and 2040The Breast, 2022
- Clinical characteristics and survival outcome of patients with estrogen receptor low positive breast cancerThe Breast, 2022
- Comparison of Estrogen receptors, Progesterone receptors and HER2-neu immunohistochemistry results in breast cancer with those of Oncotype DxAnnals of Diagnostic Pathology, 2020
- Skin Tumours2017
- Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trialsBreast Cancer Research and Treatment, 2015
- High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast CancerClinical Breast Cancer, 2015
- Differential expression of progesterone receptor, FOXA1, GATA3, and p53 between pre- and postmenopausal women with estrogen receptor-positive breast cancerBreast Cancer Research and Treatment, 2014
- Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotypeBreast Cancer Research and Treatment, 2011
- Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer StudyJAMA, 2006